



Three Teleconferences on

Community-Associated Methicillin-Resistant *Staphylococcus aureus* (CA-MRSA)

October 19, 2006

CA-MRSA: CLINICAL CHALLENGES

October 24, 2006

EPIDEMIOLOGY OF CA-MRSA IN THE UNITED STATES

November 1, 2006

LABORATORY DETECTION OF MRSA: IS IT OR ISN'T IT?

LABORATORY LEARNING LINKS TELECONFERENCE

Sponsored by the National Laboratory Training Network

DESCRIPTION

Infections with methicillin-resistant *Staphylococcus aureus* (MRSA) are common in hospitalized and nursing home patients. New strains of MRSA unrelated to isolates commonly encountered in healthcare facilities have been identified as the cause of serious outbreaks in otherwise healthy populations. This three part series will describe pathogenesis and types of infections associated with community-associated MRSA (CA-MRSA). Discussion will include therapy, prevention, and control of MRSA infections. Description of national surveillance data and recent outbreaks will highlight factors associated with transmission of CA-MRSA within healthcare facilities. Case studies will be used to highlight appropriate laboratory testing and reporting practices, application of rapid tests, detection of *mecA* and/or PBP2a, unique features of CA-MRSA isolates, options for processing surveillance specimens, and compilation of cumulative antibiogram data for MRSA.

AUDIENCE

These intermediate-level programs are appropriate for clinical and public health laboratorians, pathologists, infection control practitioners, clinicians, pharmacists, residents, and students.

<div>CA-MRSA: CLINICAL CHALLENGES</div> <div>OCTOBER 19, 2006 1:00 – 2:30 p.m. (ET)*</div> <div>AGENDA</div> <div>1:00 Pathogenesis of and infections caused by community-associated MRSA</div> <div>1:45 Treatment and prevention of community-associated MRSA</div> <div>2:30 Adjourn</div> <div>FACULTY</div> <div>John Jernigan, MD Chief, Interventions & Evaluation Section Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention Atlanta GA, Assistant Professor of Medicine, Emory University, Atlanta GA</div> <div>OBJECTIVES</div> <div>At the conclusion of this program, participants will be able to</div> <div><ul style="list-style-type: none">describe the pathogenesis of community-associated MRSA.describe current recommendations for therapy of community-associated MRSA.</div>	<div>EPIDEMIOLOGY OF CA-MRSA IN THE UNITED STATES</div> <div>OCTOBER 24, 2006 1:00 – 2:30 p.m. (ET)*</div> <div>AGENDA</div> <div>1:00 Epidemiology of community-associated MRSA in the United States</div> <div>2:00 Prevention and control of community-associated MRSA</div> <div>2:30 Adjourn</div> <div>FACULTY</div> <div>Monina Klevens, DDS, MPH, Healthcare Outcomes Branch, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta GA</div> <div>OBJECTIVES</div> <div>At the conclusion of this program, participants will be able to</div> <div><ul style="list-style-type: none">describe national surveillance programs for community-associated MRSA.describe estimated incidence and prevalence of community-associated MRSA.</div>	<div>LABORATORY DETECTION OF MRSA: IS IT OR ISN'T IT?</div> <div>NOVEMBER 1, 2006 1:00 – 2:30 p.m. (ET)*</div> <div>AGENDA</div> <div>1:00 Laboratory detection of MRSA</div> <div>2:00 Effective reporting of MRSA; the patient report and the cumulative antibiogram</div> <div>2:30 Adjourn</div> <div>FACULTY</div> <div>Janet Hindler, MCLS, MT(ASCP) Sr. Specialist, Clinical Microbiology, UCLA Medical Center, Los Angeles, CA</div> <div>OBJECTIVES</div> <div>At the conclusion of this program, participants will be able to</div> <div><ul style="list-style-type: none">describe phenotypic and gene based tests to detect MRSA.describe the use of CLSI M39-A2 to determine rates of MRSA among various patient populations.</div>
---	---	---

*All times are listed in Eastern Time. Please adjust for your time zone.

- SITE REGISTRATION**
- Registration fee per site (for one phone line): \$50.00 per teleconference (payable to APHL)
 - Select a Site Facilitator. This needs to be someone who can receive all communication via e-mail.
 - Site Facilitator must register online at <http://www.nltn.org/courses>. If you have difficulty with the online registration process, please send an e-mail to registrar@aphl.org or telephone 240-485-2727 between 8:00 a.m. – 4:30 p.m. (ET).
 - After your facility's registration is confirmed, the Site Facilitator will receive all necessary instructions and paperwork by e-mail.
 - Registration deadline is Oct. 10, 2006 (for Oct.19, 2006 program), Oct. 14, 2006 (for Oct. 24, 2006 program), and Oct. 23, 2006 (for Nov. 1, 2006 program).
 - For additional information, send an e-mail to neoffice@nltn.org or telephone 617-983-6285.

SPECIAL NEEDS

In compliance with the Americans with Disabilities Act, individuals needing special accommodations should notify the NLTN office at 617-983-6278 at least two weeks prior to the program.

CONTINUING EDUCATION

The Association of Public Health Laboratories (APHL) is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. Participants will be awarded 1.5 contact hours for each program they successfully complete. P.A.C.E. is accepted by all licensure states except Florida. Florida continuing education credit will be offered based on 1.5 hours of instruction.